Kairos Pharma, Ltd. Common Stock (KAPA)

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, presented preclinical data on its investigational compounds KROS 101 and KROS 401 at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from Feb. 23-26, 2025. The data highlighted KROS 101’s ability to inhibit tumor growth and boost T cell responses in melanoma and glioblastoma models, while KROS 401 demonstrated potential in reprogramming macrophages to counter tumor growth in glioma-bearing mice. Company executives emphasized the significance of these findings in advancing immunotherapy approaches for hard-to-treat cancers.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from February 23-26, 2025. The data highlighted positive preclinical outcomes with the Company’s glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist KROS101 in melanoma and glioblastoma as well as its peptide inhibitor for macrophages KROS 401 in glioma animal models.

Kairos Pharma (NYSE American: KAPA) announced that Cedars-Sinai Medical Center, through its academic partnership with the company, has received $600,000 from the Department of Defense Lung Cancer Research Program to support the development of ENV205. This first-in-class therapy aims to counteract chemotherapy drug resistance and cachexia, a severe muscle-wasting condition affecting cancer patients. The funding will accelerate research efforts to enhance the effectiveness of cancer treatments by targeting key metabolic pathways. CEO Dr. John Yu emphasized the company’s strategy of leveraging non-dilutive federal funding to drive drug development.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205, a groundbreaking new drug to treat chemotherapy drug resistance and cachexia.

Kairos Pharma (NYSE American: KAPA) has added Huntsman Cancer Institute in Salt Lake City as a site for its Phase 2 clinical trial of ENV105 for castrate-resistant prostate cancer. The trial, supported by the National Cancer Institute, evaluates ENV105 in combination with apalutamide. Chief Scientific Officer Dr. Neil Bhowmick emphasized Huntsman’s role in expanding patient access and advancing biomarker research. CEO Dr. John Yu highlighted the addition as a key milestone in addressing resistance to hormone therapy in prostate cancer treatment.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.

Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference. The study demonstrated that KROS 101 enhances T cell infiltration, proliferation, and tumor-killing ability in melanoma and glioblastoma models while reducing regulatory T-cell suppression. Compared to the GITR antibody TRX518, KROS 101 showed superior tumor reduction in a human GITR knock-in mouse model. The company sees potential for the therapy to expand T cell responses and improve cancer treatment, supporting further clinical development.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced it will present during the plenary session of the 13th AACR-JCA Joint Conference, “From Cancer Discovery Science to Therapeutic Innovation,” taking place Feb. 1-5, 2025, in Maui, Hawaii. The presentation, titled “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,” is scheduled for Feb. 5 at 4:00 p.m. local time. The conference brings together leading researchers from the U.S., Japan, and beyond to showcase advancements in cancer research.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii.

Kairos Pharma (NYSE American: KAPA) reflected on its 2024 progress and outlined key 2025 milestones in a letter to shareholders. Last year’s achievements included its initial public offering, collaborations with PreCheck Health Services and City of Hope Cancer Center, and advancements in clinical trials for ENV105 targeting prostate and lung cancers. Notable developments also included the first patient dosed in a combination therapy with Osimertinib, expanded patent coverage, and initiation of research coverage by leading analysts. Looking ahead, Kairos aims to advance Phase 2 trials for prostate cancer and Phase 1 trials for non-small cell lung cancer, with safety data expected in the first half and year-end, respectively. The company also plans to present findings at scientific meetings, progress pre-IND studies for KROS 101, and pursue strategic partnerships, emphasizing its commitment to innovative therapies addressing cancer resistance and immune suppression.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders:

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick will present a corporate overview at the Lytham Partners Investor Healthcare Summit on Jan. 13, 2025. The conference will be held virtually.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer, will present a corporate overview at the Lytham Partners Investor Healthcare Summit. The conference is being held virtually on January 13, 2025.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, was featured in an EF Hutton report that initiated coverage with a buy rating and a price target of $9.00 per share. EF Hutton, which recently rebranded to D. Boral Capital LLC, is an investment bank dedicated to providing exceptional strategic advice and financing solutions to middle market and emerging growth companies around the globe.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, is spotlighted today in a Rodman & Renshaw, LLC report that initiated coverage with a buy rating and a price target of $12.00 per share. Based in New York City, Rodman & Renshaw is a full-service investment bank with a heritage spanning over 70 years.

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.

Kairos Pharma (NYSE American: KAPA) has announced its participation in The Microcap Conference 2025, set for January 28-30 at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company’s management team will present recent developments, growth strategies, and investment opportunities, while engaging in one-on-one meetings with investors. The Microcap Conference, the largest independent microcap event in the U.S., features keynote speakers, expert panels, and networking opportunities, with highlights including insights from Jon Ledecky, Tom Gardner, and financial commentators, as well as entertainment from comedian Tom Papa.

Kairos Pharma (NYSE American: KAPA) announced the inclusion of City of Hope Cancer Center in California in its Phase 2 clinical trial for ENV105, targeting castrate-resistant prostate cancer. The trial, supported by Kairos Pharma and a National Cancer Institute grant, evaluates ENV105’s potential to overcome hormone therapy resistance in combination with apalutamide. Adding City of Hope allows for a broader patient population and the identification of biomarkers to optimize treatment. Kairos executives highlighted the strong preclinical evidence and collaboration with City of Hope’s expert oncologists as pivotal steps in developing innovative therapies for patients resistant to standard hormone treatments.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.

Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics. The company’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. With a robust pipeline, experienced leadership, as well as an intellectual property portfolio extending to 2040, Kairos Pharma is uniquely positioned to address widespread challenges in oncology, including the $11.3 billion prostate cancer and $14 billion lung cancer markets and the $118 billion immunotherapy sector.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, is dedicated to advancing innovative oncology therapies to overcome critical challenges in cancer drug resistance and immune suppression, two significant challenges to effective cancer treatment. With an extensive intellectual property portfolio valid until 2035 to 2040, the company is developing a notable pipeline of drugs tackling cancer drug resistance with a focus on overcoming impacting widespread cancers, including prostate and lung cancer, as well as reversing immune suppression.

Kairos Pharma (KAPA) announced its approval for a dual listing on Upstream, a MERJ Exchange market and global securities trading app, with trading set to begin on November 26 under the ticker symbol ‘KAPA.’ The listing aims to broaden Kairos Pharma’s investor base beyond the U.S., enhance liquidity, and facilitate price discovery. Investors can prepare to trade by signing up on Upstream and completing KYC verification. CEO Dr. John Yu highlighted the dual listing as a strategic move to build shareholder value while advancing the company’s lead drug, ENV105, for cancer treatment through clinical trials and commercialization.

The global oncology landscape is on the brink of transformation, with cancer cases expected to rise sharply, particularly in lower-income countries, where the number of new cases could soar to 32 million annually by 2050. This growing demand for cancer treatments has driven global spending on oncology medicines to $223 billion in 2023, with a projected increase to $409 billion by 2028. The launch of 25 novel oncology drugs in 2023, along with over 2,000 new clinical trials, highlights a dynamic period of innovation in the sector. Breakthrough therapies, including cell and gene therapies, antibody-drug conjugates, and radioligand treatments, show significant promise but remain unevenly accessible. As oncology treatments continue to evolve at a rapid pace, this environment presents a unique window of opportunity for investors to explore emerging biopharma companies, which are positioned to lead the charge in addressing unmet medical needs in cancer care.